SAMDaily.us | SRCSGT | Q | Custom Cloning and lentiviral preparation services for the development of assays and therapeutics for NGYL1 disease for the Therapeutic Development Branch (TDB) at the National Center for Advancing Translational Sciences (NCATS).

SAMDAILY.US - ISSUE OF MARCH 18, 2021 SAM #7049
SOURCES SOUGHT

Q -- Custom Cloning and lentiviral preparation services for the development of assays and therapeutics for NGYL1 disease for the Therapeutic Development Branch (TDB) at the National Center for Advancing Translational Sciences (NCATS).

Notice Date: 3/16/2021 3:47:27 AM
Notice Type: Sources Sought
NAICS: 541380 — Testing Laboratories
Contracting Office: NATIONAL INSTITUTES OF HEALTH NIDA Bethesda MD 20892 USA
ZIP Code: 20892
Solicitation Number: 75N95021Q00106
Response Due: 3/31/2021 12:00:00 PM
Archive Date: 04/15/2021
Point of Contact: Jeanette Russell, Phone: (301) 827-5140
E-Mail Address: Jeanette.Russell@nih.gov
(Jeanette.Russell@nih.gov)
Description: This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition.� It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract.� Responses will not be considered as proposals or quotes.� No award will be made as a result of this notice.� The Government will NOT be responsible for any costs incurred by the respondents to this notice.� This notice is strictly for research and information purposes only. Background:� This request is for custom cloning and lentiviral preparation services for the development of assays and therapeutics for NGYL1 disease for the Therapeutic Development Branch (TDB) at the National Center for Advancing Translational Sciences (NCATS). Purpose and Objectives: NCATS focuses on getting more treatments to more patients more quickly. Several thousand genetic diseases affect humans, of which only about 500 have any treatment. NCATS is directly addressing this problem by discovering new technologies and other approaches that could greatly accelerate the process of developing and deploying solutions that can be used by all translational researchers. Within NCATS, the TDB biology group works to encourage and speed the development of new treatments for diseases with high-unmet medical needs. This acquisition specifically addresses the new therapeutic for NGLY1 rare disease project, which specifically applies breakthroughs in translational science to advancing new treatments for rare diseases. TDB biology is requesting a service to clone genes of interest into lentiviral vector and lentiviral preparations for the same. The contractor will custom clone three different types of constructs, prepare mega-scale endo-free DNA preparation as well as lentiviral particles at >10^9 IFUs/mL. These lentiviral preparations will be used at NCATS to test two different therapeutic approaches for the NGLY1 disease: One of the constructs and its lentiviral preparation will be used to develop a cell-based assay adapted from researchers at Yale University. Two other constructs and their lentiviral preparation will be used to test potential RNA therapy for the NGLY1 disease. Project requirements: PCR cloning of the NGLY1 from pcDNA3.1-Hygro-NGLY1 template into pCDH-CMV-MCS-EF1?-GreenPuro (Ampicillin) via 5� NheI and 3� NotI by recombination, with sequence verification across the insert (1985bp); making NGLY1 in pCDH-CMV-MCS-EF1?-GreenPuro and delivered as an endo-free mega-scale DNA sample. PCR cloning of the NGLY1-Del8 from pcDNA3.1-Hygro-NGLY1-Del8 template into pCDH-CMV-MCSEF1?-GreenPuro (Ampicillin) via 5� NheI and 3� NotI by recombination, with sequence verification across the insert (1874bp); making NGLY1-Del8 in pCDH-CMV-MCS-EF1?-GreenPuro and delivered as an endo-free mega-scale DNA sample. PCR cloning of the ss-Rluc-C124-N290 from pcDNA-ss-Rluc-C124-N290 template into pCDH-CMVMCS-EF1?-GreenPuro (Ampicillin) via 5� NheI and 3� NotI by recombination, with sequence verification across the insert (1016bp); making ss-Rluc-C124-N290 in pCDH-CMV-MCS-EF1?-GreenPuro and delivered as an endo-free mega-scale DNA sample. PCR cloning of the NGLY1 from pcDNA3.1-Hygro-NGLY1 template into EF1?-MCS-T2A-GFP (Ampicillin) via 5� NheI and 3� NotI by recombination, with sequence verification across the insert (1985bp); making NGLY1 in EF1?-MCS-T2A-GFP and delivered as an endo-free mega-scale DNA sample. PCR cloning of the NGLY1-Del8 from pcDNA3.1-Hygro-NGLY1-Del8 template into EF1?-MCS-T2AGFP (Ampicillin) via 5� NheI and 3� NotI by� recombination, with sequence verification across the insert (1874bp); making NGLY1-Del8 in EF1?-MCS-T2A-GFP and delivered as an endo-free mega-scale DNA sample. PCR cloning of the ss-Rluc-C124-N290 from pcDNA-ss-Rluc-C124-N290 template into EF1?-MCST2A-GFP (Ampicillin) via 5� NheI and 3� NotI by recombination, with sequence verification across the insert (1016bp); making ss-Rluc-C124-N290 in EF1?-MCS-T2A-GFP and delivered as an endo-free mega-scale DNA sample. Lentivirus packaging with 3rd generation packaging system and the above 6 constructs. Ten 25?L aliquots (250?L total) of VSV-G pseudotyped lentiviral particles at >10^9 IFUs/ml titer will be provided, along with titer measurement based on infectious particles. Lentivirus packaging with 3rd generation packaging system and Firefly luciferase control, CMV-rFLuc-T2A-EGFP-mPKG-Puro. Ten 25?L aliquots (250?L total) of VSV-G pseudotyped lentiviral particles at >10^9 IFUs/ml titer will be provided, along with titer measurement based on infectious particles. PCR cloning of the NGLY1 from pcDNA3.1-Hygro-NGLY1 template into pLenti-P2A-tGFP (Chloramphenicol) via 5� NheI and 3� NotI by recombination, with sequence verification across the insert (1984bp); making NGLY1 in pLenti-P2A-tGFP and delivered as an endo-free mega-scale DNA sample. PCR cloning of the NGLY1-Del8 from pcDNA3.1-Hygro-NGLY1-Del8 template into pLenti-P2A-tGFP (Chloramphenicol) via 5� NheI and 3� NotI by recombination, with sequence verification across the insert (1873bp); making NGLY1-Del8 in pLenti-P2A-tGFP and delivered as an endo-free mega-scale DNA sample. PCR cloning of the ss-Rluc-C124-N290 from pcDNA-ss-Rluc-C124-N290 template into pLenti-P2AtGFP (Chloramphenicol) via 5� NheI and 3� NotI by recombination, with sequence verification across the insert (1015bp); making ss-Rluc-C124-N290 in pLenti-P2A-tGFP and delivered as an endo-free megascale DNA sample. PCR cloning of the NGLY1 from pcDNA3.1-Hygro-NGLY1 template into pEF1alpha-IRES-ZsGreen1 (Kanamycin) via 5� EcoRI and 3� BamHI by recombination, with sequence verification across the insert (1983bp); making NGLY1 in pEF1alpha-IRES-ZsGreen1 and delivered as an endo-free mega-scale DNA sample. PCR cloning of the NGLY1-Del8 from pcDNA3.1-Hygro-NGLY1-Del8 template into pEF1alpha-IRESZsGreen1(Kanamycin) via 5� EcoRI and 3� BamHI by recombination, with sequence verification across the insert (1872bp); making NGLY1-Del8 in pEF1alpha-IRES-ZsGreen1 and delivered as an endo-free mega-scale DNA sample. PCR cloning of the ss-Rluc-C124-N290 from pcDNA-ss-Rluc-C124-N290 template into pEF1alpha-IRES-ZsGreen1 (Kanamycin) via 5� EcoRI and 3� BamHI by recombination, with sequence verification across the insert (1014bp); making ss-Rluc-C124-N290 in pEF1alpha-IRES-ZsGreen1 and delivered as an endo-free mega-scale DNA sample. Anticipated period of performance: Three months from date of award. Capability statement /information sought. Respondents must provide, as part of their response, a capability statement that clearly identifies information regarding: (a) staff expertise, including their availability, experience, and formal and other training; (b) current in-house capability and capacity to perform the work; (c) prior completed projects of similar nature; (d) corporate experience and management capability; and (e) examples of prior completed Government contracts, references, and other related information. Please note that NCATS is particularly interested in small business sources. If you are a small business, please state the type of small business (small business; HUBZone; service-disabled, veteran-owned; 8(a); veteran-owned; woman-owned; or small disadvantaged businesses) and your size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. The respondent must also provide their� DUNS number, organization name, address, point of contact, and size and type of business (e.g., 8(a), HubZone, etc., pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2� x 11� paper size, with 1� top, bottom, left and right margins, and with single or double spacing. The information submitted must be in an outline format that addresses each of the elements of the project requirements and in the capability statement /information sought paragraphs stated herein.� A cover page and an executive summary may be included but is not required. The response is limited to ten (10) pages.� The 10-page limit does not include the cover page, executive summary, or references, if requested. The response must include the respondents� technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and e-mail addresses. All responses to this notice must be submitted electronically to the Contract Specialist.� Facsimile responses are NOT accepted. The response must be submitted to Jeanette Russell, Contract Specialist, at e-mail address Jeanette.Russell@nih.gov. The response must be received on or before March 31, 2021 at 3:00 pm, Eastern Time. �Disclaimer and Important Notes:� This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization�s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).�
Web Link: SAM.gov Permalink
(https://beta.sam.gov/opp/8b9a594c246f4da48b15c7416f555a54/view)
Place of Performance: Address: Rockville, MD 20850, USA; Zip Code: 20850; Country: USA
Record: SN05944730-F 20210318/210316230123 (samdaily.us)
Source: SAM.gov Link to This Notice
(may not be valid after Archive Date)

| FSG Index | This Issue's Index | Today's SAM Daily Index Page |

Loren Data's SAM Daily™

Q -- Custom Cloning and lentiviral preparation services for the development of assays and therapeutics for NGYL1 disease for the Therapeutic Development Branch (TDB) at the National Center for Advancing Translational Sciences (NCATS).